TickerFacts.

Relay Therapeutics, Inc. (RLAY): Revenue

Annual figures by period end, from SEC filings.

$15.36M
Year ended 2025-12-31
$10.35M
Trailing 12 months to 2026-06-30
+123.2%
3-year compound annual growth
-28.6%
5-year compound annual growth
$82.65M2020-12-31: $82.65M2021-12-31: $3.03M2022-12-31: $1.38M2023-12-31: $25.55M2024-12-31: $10.01M2025-12-31: $15.36M$15.36M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$15.36M+53.4%2026-02-26, From 2025-01-01
2024-12-31$10.01M-60.8%2026-02-26, From 2024-01-01
2023-12-31$25.55Mn/m2026-02-26, From 2023-01-01
2022-12-31$1.38M-54.4%2025-02-26, From 2022-01-01
2021-12-31$3.03M-96.3%2024-02-22, From 2021-01-01
2020-12-31$82.65Mn/a2023-02-23, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Relay Therapeutics, Inc. (RLAY)2025-12-31$15.36M+53.4%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$14.56M+53.2%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$16.80Mn/a
LENZ Therapeutics, Inc. (LENZ)2025-12-31$19.09Mn/a
Alector, Inc. (ALEC)2025-12-31$21.05M-79.1%
Caribou Biosciences, Inc. (CRBU)2025-12-31$11.16M+11.7%
TScan Therapeutics, Inc. (TCRX)2025-12-31$10.32M+266.7%
Alpha Cognition Inc. (ACOG)2025-12-31$10.22Mn/a
Taysha Gene Therapies, Inc. (TSHA)2025-12-31$9.77M+17.3%

Compare RLAY, LCTX, PTHS, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗